Today we look at one noteworthy recent insider buy. On Wednesday, VYNE Therapeutics', Patrick G. Lepore, made a $43,800 buy of VYNE, purchasing 15,000 shares at a cost of $2.92 each. Bargain ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on ...

The VYN201 gel is intended to treat non-segmental vitiligo. Credit: Prostock-studio / Shutterstock. US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase ...

06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to ...